These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21632858)

  • 1. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Trarbach T; Folprecht G; Shi MM; Lebwohl D; Jalava T; Laurent D; Meinhardt G; Harris AL
    Clin Cancer Res; 2011 Jul; 17(14):4892-900. PubMed ID: 21632858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Gatter KC; Trarbach T; Folprecht G; Shi MM; Lebwohl D; Jalava T; Laurent D; Meinhardt G; Harris AL;
    Br J Cancer; 2012 Sep; 107(7):1044-50. PubMed ID: 22910317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
    Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
    Scott EN; Meinhardt G; Jacques C; Laurent D; Thomas AL
    Expert Opin Investig Drugs; 2007 Mar; 16(3):367-79. PubMed ID: 17302531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
    J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer.
    Koukourakis MI; Kakouratos C; Kalamida D; Bampali Z; Mavropoulou S; Sivridis E; Giatromanolaki A
    Int J Radiat Biol; 2016 Jul; 92(7):353-63. PubMed ID: 27010533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
    Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
    Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
    Tyagi P
    Clin Colorectal Cancer; 2005 May; 5(1):24-6. PubMed ID: 15929803
    [No Abstract]   [Full Text] [Related]  

  • 13. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1.
    Kayser G; Kassem A; Sienel W; Schulte-Uentrop L; Mattern D; Aumann K; Stickeler E; Werner M; Passlick B; zur Hausen A
    Diagn Pathol; 2010 Apr; 5():22. PubMed ID: 20385008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis.
    Lu R; Jiang M; Chen Z; Xu X; Hu H; Zhao X; Gao X; Guo L
    PLoS One; 2013; 8(9):e74853. PubMed ID: 24086384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M; Roodhart JM; Voest EE
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer.
    Kim HS; Lee HE; Yang HK; Kim WH
    Pathobiology; 2014; 81(2):78-85. PubMed ID: 24401755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
    Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
    Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients.
    Sun X; Sun Z; Zhu Z; Guan H; Zhang J; Zhang Y; Xu H; Sun M
    PLoS One; 2014; 9(3):e91068. PubMed ID: 24608789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
    Koukourakis MI; Giatromanolaki A; Simopoulos C; Polychronidis A; Sivridis E
    Clin Exp Metastasis; 2005; 22(1):25-30. PubMed ID: 16132575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.